CIRM Webinars, Workshops & Publications
Webinars and Workshops
- February 4, 2016: CIRM Scientific and Medical Accountability Standards Working Group Workshop on Human Gene Editing
- March 18, 2015: CAR-T Cell Immunotherapy: Challenges and Opportunities Using Mature or Stem Memory T Cells
- January 21, 2015: CIRM 2.0: We Are Changing the Way We Work
- September 11, 2014: Use of Induced Pluripotent Stem Cells as Screening Tools and Therapeutics
- November 14, 2013: Cell Therapies for Parkinson’s Disease from Discovery to Clinic
- June 20, 2013: Reimbursement Strategies Webinar
- April 15, 2013: Clinical Trials: Moving Stem Cell Based Therapies to the Clinic
- September 27, 2012: Immune Response in Stem Cell Therapies
- May 2, 2012: Focus on the Eye
- September 12, 2011: Scaffolding
- May 26, 2011: Imaging Technology for Cellular Therapies
- September 28, 2010: Preclinical Considerations for Stem Cell Therapies
- April 15, 2010: Issues in Product Characterization
- February 24 & 25, 2022: CIRM Central Nervous System (CNS) Consortium Workshop
- January 13, 2020 Navigating Regenerative Medicine: Highlights from the CIRM-CURA Roundtable Conversation
- September, 26, 2019: Report on CIRM Grants Working Group Program Meeting
- April 15-16, 2019: Brainstorming Neurodegeneration Workshop
- February 4, 2016: CIRM Scientific and Medical Accountability Standards Working Group Workshop on Human Gene Editing
- September 2013: International Regulatory Considerations on Development Pathways for Cell Therapies.
Contact Us
If you have questions concerning any Webinar or Roundtable content, please contact:
Esteban Cortez
510-899-0342
ecortez@cirm.ca.gov
Workshop Reports
CIRM holds workshops and meetings to explore, in-depth, scientific and policy issues within the field of stem cell research and regenerative medicine. Workshop reports summarize the findings from meetings and are designed to support scientific and policy-development programs at CIRM.
- Key Tools and Technology Hurdles in Advancing Stem-Cell Therapies
- International Regulatory Considerations on Development Pathways for Cell Therapies. Also available via AlphaMed Press.
- Creating a Cell Therapy Manufacturing Center of Excellence
- Breaking the Bottleneck: Deriving Definitive Hematopoietic Stem Cells from Human Pluripotent Stem Cells
- Engineering Strategies, Opportunities, and Challenges for Tissue Repair and Regeneration: CIRM Workshop Summary and Recommendati
- Cell Therapies for Parkinson’s Disease from Discovery to Clinic
- Alpha Stem Cell Clinics: Delivering a New Kind of Medicine
- Cerebral Palsy Workshop
- Human iPS Cell Banking Workshop
- SCNT Workshop Report
- Summary and Recommendations of the CIRM Autism Workshop
- White paper: Translational Issues for hESC-Derived Therapies
- Summary of the Clinical Trials Workshop
- 2008 Grantee Meeting Abstract Book
- CIRM Predictive Toxicology Workshop Report
- Report of the Disease Team Workshop (November 2007)
- Stem Cell Research: Charting New Directions for California (October 2005) Conference Report
- 2007 Annual CIRM Scholar Meeting
- Navigating Regenerative Medicine: Highlights from the CIRM-CURA Roundtable Conversation
- DISCUSS Workshop Report
- Ethical and Policy Considerations for A Pluripotent Stem Cell Resource Center 2011 Update (4/29/11)
- CIRM Diversity Workshop Report
- Ethical and Policy Considerations for a Pluripotent Cell Resource Center (PCRC)
- Advancing the Effective Research Oversight: 2010 Regional Workshops on Regulatory Compliance 5/11/2010
- SCRO Workshop Report 6/2008
- Advancing Effective Research Oversight: CIRM’s Evaluation Initiative 2/08/07
- Advancing Effective Research Oversight: CIRM’s Evaluation Initiative Regional Workshop Summary Report 5/10/07
Staff Publications
Our staff members publish regularly in high-profile journals where their insights help guide the field.
- Kadyk, LC; Okamura, RM; Talib, S. Enabling allogeneic therapies: CIRM-funded strategies for immune tolerance and immune evasion. Stem Cells Transl Med. 2020.
- Lin, S.S., DeLaura, S., Jones, E.M. The CIRM iPSC Repository. Stem Cell Research. 44: 101671 (2020).
- Talib S, Shepard KA. Unleashing the cure: Overcoming persistent obstacles in the translation and expanded use of hematopoietic stem cell-based therapies. Stem Cells Transl Med. 2020 Apr;9(4):420-426. doi: 10.1002/sctm.19-0375. Epub 2020 Jan 19. PMID: 31957346 Free PMC article.
- Gilberto R Sambrano, Maria T Millan; Translating Science Into the Clinic: The Role of Funding Agencies Cell Stem Cell 2020 Apr 2;26(4):479-481. doi: 10.1016/j.stem.2020.03.010. PMID: 32243807 DOI: 10.1016/j.stem.2020.03.010
- Gilberto R Sambrano, Shyam Patel, and Hayley Lam; Private and Public Funding for Bringing Regenerative Medicine to Market 2019. Encyclopedia of Tissue Engineering and Regenerative Medicine, Vol. 3 (pp.17–30). Academic Press: Elsevier.ISBN: 9780128136997
- Creasey AA, Stacey G, Bharti K, Sato Y, Lubiniecki A. A strategic road map to filing a Biologics License Application for a pluripotent stem cell derived therapeutic product. Biologicals. 2019;59:68-71. doi:10.1016/j.biologicals.2019.03.007
- Abbot S et al. Report of the international conference on manufacturing and testing of pluripotent stem cells. Biologicals. 2018 Nov;56:67-83. doi: 10.1016/j.biologicals.2018.08.004. Epub 2018 Aug 24.
- Sullivan S, Stacey GN, Akazawa C, et al. Quality control guidelines for clinical-grade human induced pluripotent stem cell lines. Regen Med. 2018;13(7):859-866. doi:10.2217/rme-2018-0095
- Jamieson CHM, Millan MT, Creasey AA, Lomax G, Donohoe ME, Walters MC, Abedi M, Bota DA, Zaia JA, Adams JS. CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. Cell Stem Cell. 2018 Jun 1;22(6):801-805. doi: 10.1016/j.stem.2018.05.007
- Perrin M, Kim T, Stan R, Giesie P, Tabor J, Le Verche V, Johnson S, Lomax GP, Zaia JA. Role of Nursing Competencies for Accelerating Clinical Trials in Stem Cell Clinics. Stem Cells Transl Med. 2018 Jan;7(1):6-10. doi: 10.1002/sctm.17-0165. Epub 2017 Nov 3.
- Kadyk LC, DeWitt ND, Gomperts B. Proceedings: Regenerative Medicine for Lung Diseases: A CIRM Workshop Report. Stem Cells Transl Med. 2017 Oct;6(10):1823-1828. doi: 10.1002/sctm.17-0047. Epub 2017 Aug 9
- Lomax, G.P., Aungst, H. (2017). “Considerations for the Use of Biospecimens in Induced Pluripotent Stem Cell Research.” in Specimen Science Ethics and Policy Implications. MIT Press.
- McCormack K. Regen Med California Institute for Regenerative Medicine Profile CIRM 2.0. Regen Med. 2016 Dec;11(8):759-762. Epub 2016 Dec 2
- Tsukamoto A, Abbot SE, Kadyk LC, DeWitt ND, Schaffer DV, Wertheim JA, Whittlesey KJ, Werner MJ. Challenging Regeneration to Transform Medicine. Stem Cells Transl Med. 2016 Jan;5(1):1-7. doi: 10.5966/sctm.2015-0180. Epub 2015 Nov 25
- Littman N, Abo A. Proceedings: Using Stem Cell Therapies to Reestablish Osteogenic Capability for Bone Regeneration. Stem Cells Transl Med. 2015 Nov;4(11):1247-50. doi: 10.5966/sctm.2015-0202. Epub 2015 Oct 19
- Collins LR, Priest C, Caras I, Littman N, Kadyk L. Proceedings: Moving Toward Cell-Based Therapies for Heart Disease. Stem Cells Transl Med. 2015 Aug;4(8):863-7. doi: 10.5966/sctm.2015-0118. Epub 2015 Jul 1
- Pappas DJ, Gourraud PA, Le Gall C, Laurent J, Trounson A, DeWitt N, Talib S. Proceedings: human leukocyte antigen haplo-homozygous induced pluripotent stem cell haplobank modeled after the california population: evaluating matching in a multiethnic and admixed population. Stem Cells Transl Med. 2015 May;4(5):413-8. doi: 10.5966/sctm.2015-0052
- Shepard KA. Proceedings: the SEED grant program: a brief synopsis of the outcomes and impact of CIRM’s first research initiative. Stem Cells Transl Med. 2015 Mar;4(3):211-6. doi: 10.5966/sctm.2014-0299. Epub 2015 Feb 2.
- Lomax GP, Hull SC, Isasi R. The DISCUSS Project: Revised Points to Consider for the Derivation of Induced Pluripotent Stem Cell Lines From Previously Collected Research Specimens. Stem Cells Transl Med. 2015 Feb;4(2):123-9. doi: 10.5966/sctm.2014-0192. Epub 2015 Jan 5.
- Kadyk LC, Collins LR, Littman NJ, Millan MT. Proceedings: moving toward cell-based therapies for liver disease. Stem Cells Transl Med. 2015 Mar;4(3):207-10. doi: 10.5966/sctm.2014-0276. Epub 2015 Jan 30
- Talib S, Millan MT, Jorgenson RL, Shepard KA. Proceedings: Immune Tolerance and Stem Cell Transplantation: A CIRM Mini-Symposium and Workshop Report. Stem Cells Transl Med. 2015 Jan;4(1):4-9. doi: 10.5966/sctm.2014-0262. Epub 2014 Dec 3.
- Caras IW, Littman N, Abo A. Proceedings: debilitating eye diseases. Stem Cells Transl Med. 2014 Dec;3(12):1393-7. doi: 10.5966/sctm.2014-0221. Epub 2014 Nov 6
- Feigal EG, Tsokas K, Viswanathan S, Zhang J, Priest C, Pearce J, Mount N. Proceedings: international regulatory considerations on development pathways for cell therapies. Stem Cells Transl Med. 2014 Aug;3(8):879-87. doi: 10.5966/sctm.2014-0122. Epub 2014 Jul 18.
- Grieshammer U, Shepard KA. Proceedings: consideration of genetics in the design of induced pluripotent stem cell-based models of complex disease. Stem Cells Transl Med. 2014 Nov;3(11):1253-8. doi:10.5966/sctm.2014-0191
- Canet-Aviles R, Lomax GP, Feigal EG, Priest C. Proceedings: cell therapies for Parkinson’s disease from discovery to clinic. Stem Cells Transl Med. 2014 Sep;3(9):979-91. doi: 10.5966/sctm.2014-0146. Epub 2014 Aug 22
- Feigal EG, DeWitt ND. The proceedings of the California Stem Cell Agency. Stem Cells Transl Med. 2014 Jun;3(6):671-2. doi: 10.5966/sctm.2014-0068. Epub 2014 Apr 25
- Lomax GP, DeWitt ND, Millan MT, Feigal EG. How California Institute for Regenerative Medicine research programs support science and regulatory policy. Stem Cells Transl Med. 2014 Jun;3(6):673-4. doi: 10.5966/sctm.2014-0069. Epub 2014 Apr 25
- Shepard KA, Talib S. Bottlenecks in deriving definitive hematopoietic stem cells from human pluripotent stem cells: a CIRM mini-symposium and workshop report. Stem Cells Transl Med. 2014 Jul;3(7):775-81. doi: 10.5966/sctm.2014-0104
- Lomax GP, DeWitt ND. Somatic cell nuclear transfer in Oregon: expanding the pluripotent space and informing research ethics. Stem Cells Dev. 2013 Dec;22 Suppl 1:25-8. doi: 10.1089/scd.2013.0402.
- Lomax GP, Hull SC, Lowenthal J, Rao M, Isasi R. The DISCUSS Project: induced pluripotent stem cell lines from previously collected research biospecimens and informed consent: points to consider. Stem Cells Transl Med. 2013 Oct;2(10):727-30. doi: 10.5966/sctm.2013-0099. Epub 2013 Aug 29.
- Trounson A, DeWitt ND. Pluripotent stem cells from cloned human embryos: success at long last. Cell Stem Cell. 2013 Jun 6;12(6):636-8. doi: 10.1016/j.stem.2013.05.022. Erratum in: Cell Stem Cell. 2013 Aug 1;13(2):255
- Lomax GP, Trounson AO. Correcting misperceptions about cryopreserved embryos and stem cell research. Nat Biotechnol. 2013 Apr;31(4):288-90. doi: 10.1038/nbt.2541
- Lomax GP, Shepard KA. Return of results in translational iPS cell research: considerations for donor informed consent. Stem Cell Res Ther. 2013 Jan 21;4(1):6. doi: 10.1186/scrt154. Review.
- Trounson A, Baum E, Gibbons D, Tekamp-Olson P. Developing a case study model for successful translation of stem cell therapies. Cell Stem Cell. 2010 Jun 4;6(6):513-6. doi: 10.1016/j.stem.2010.05.008
- Scheiner Z, Talib S, Feigal E. The Potential for Immunogenicity of Autologous Induced Pluripotent Stem Cell Derived Therapies. J Biol Chem. 2013 Dec 20
- Trounson A, Shepard KA, DeWitt ND. Human disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev. 2012 Oct;22(5):509-16.
- Patel R, Lomax G (2011) Use of hESC Lines by CIRM Grantees: The Value of Embryonic Stem Cell Research Oversight (ESCRO) Committees. J Stem Cell Res Ther 1:107.
- Lomax GP, Trounson AO. Correcting misperceptions about cryopreserved embryos and stem cell research. Nat Biotechnol. 2013 Apr;31(4):288-90.
- Lomax GP, Shepard KA. Return of results in translational iPS cell research: considerations for donor informed consent.Stem Cell Res Ther. 2013 Jan 21;4(1):6.
- Lomax GP. The Great ESCRO Experiment: There Is Still Value to Be Gained. Am J Bioeth. 2013 Jan;13(1):55-6
- Feigal EG, Tsokas K, Zhang J, Cromer MV, Whittlesey KJ, Werner MJ. Perspective: communications with the Food and Drug Administration on the development pathway for a cell-based therapy: why, what, when, and how? Stem Cells Transl Med. 2012 Nov;1(11):825-32.
- Whittlesey KJ, Witten C. US FDA outreach to the regenerative medicine community: challenges and opportunities. Regen Med. 2012 Jul;7(4):595-603.
- Frey-Vasconcells J, Whittlesey KJ, Baum E, Feigal EG. Translation of stem cell research: points to consider in designing preclinical animal studies. Stem Cells Transl Med. 2012 May;1(5):353-8.
- DeWitt ND, Trounson A. Direct conversion in the heart: a simple twist of fate. EMBO J. 2012 Apr 20;31(10):2244-6
- Trounson A, Dewitt ND. Stem cell biology: Towards the reality of cell therapeutics. Nat Cell Biol. 2012 Apr 2;14(4):331
- Trounson A. California institute for regenerative medicine: accelerating stem cell therapies in California and beyond. Stem Cells. 2012 Mar;30(3):357-9
- Dewitt ND, Yaffe MP, Trounson A. Building stem-cell genomics in California and beyond. Nat Biotechnol. 2012 Jan 9;30(1):20-5
- Trounson A, Grieshammer U. (2012) Chimeric primates: embryonic stem cells need not apply. Cell. 2012 Jan 20;148(1-2):19-21
- Koch NJ, Baum E, Trounson A. (2011) European court ruling on embryonic stem cells: ripple effects. Cell Stem Cell. 2011 Dec 2;9(6):499-500
- Lyrawati D, Trounson A, Cram D. (2011) Expression of GFP in the mitochondrial compartment using DQAsome-mediated delivery of an artificial mini-mitochondrial genome. Pharm Res. Nov;28(11):2848-62.
- Adams A, Lomax G, Sanatarini A (2011) Social media and stem cell science: examining the discourse. Regen Med. 6(6SuppL.):121-124
- Grieshammer U, Shepard KA, Nigh A,Trounson AO (2011) Finding the niche for human somatic cell nuclear transfer. Nature Biotech 2011 Aug 5;29(8):701-5.
- Lomax, G.P., Peckman, S.R. (2011) Stem Cell Policy Exceptionalism: Proceed with Caution. Stem Cell Reviews and Reports. Vol. 5, No. 1.
- Robson J, Trounson A (2011) The potential of stem cells for 21st century neuroscience. Special Issue: Stem Cells in Neuroscience. Neurochem Int. Sep;59(3):327-8.
- Trounson A (2011) CIRM the way ahead. Regen Med. May;6(3):285-90.
- Trounson A, Baum E (2011) Regulatory Challenges – The Survey Says. EBR (in press)
- Trounson A, DeWitt N, Feigal EG (2011) A New Model Needed for the Delivery of Stem Cell Therapies in Translation for Regenerative Medicine – The Alpha Stem Cell Clinic. Stem Cells Translation Med (in press)
- Trounson A, Thakar R, Lomax G, Gibbons D (2011) Clinical trials for stem cell therapies. BMC Med. 2011 May 10;9(1):52.
- Carson S, Eschenbach D, Lomax G, Rice V, Sauer M, Taylor R (2010) Proposed oocyte donation guidelines for stem cell research. ASRM Fertility and Sterility. Vol 94, No7.
- Klein R N , Trounson A (2010) A new political-financial paradigm for medical research: the California model. . In C. Prescott and I Polak, eds., The Delivery of Regenerative Medicines and Their Impact on Healthcare. London: Taylor & Francis Group, LLC pp 11-33.
- Lomax, G.P. (2010) Stem Cell Research: A Platform for Science-Policy Innovation. Stanford Journal of Law, Science and Policy. March 2010
- Lomax, G.P. (2010) Rejuvenated Federalism: State-Based Stem Cell Research Policy. In Contested Cells: Global Perspectives on the Stem Cell Debate: Capps B.J., Campbell A.V.editors.
- Trounson A, Baum E, Gibbons D, Tekamp-Olson P (2010) Developing a model for successful translation of stem cell therapies. Cell Stem Cell 6(6):513-6.
- Martell K, Trounson A, Baum E (2010) Stem cell therapies in clinical trials: Workshop on best practices and the need for harmonization. Cell Stem Cell 7(4):451-4
- Tekamp-Olson P, Canet-Aviles, Collins L R, Steffen B J, Talib S, Trounson A (2010) Challenges in taking embryonic stem cells from bench to clinic. In: Stem Cells From Bench to Bedside (Second Edn) A Bongso, E H Lee eds.
- Trounson A.(2010) Law, Ethics, Religion, and Clinical Translation in the 21st Century. Stem Cells. Jan 8;28(1):2.
- Trounson A (2009) Rats, Cats, and elephants, but still no unicorn: Induced pluripotent stem cells from new species. Cell Stem Cell. Jan 9;4(1):3-4.
- Trounson A (2009) New perspectives in human stem cell therapeutic research. BMC Med. 2009 Jun 11;7:29-33.
- Lomax, G.P., McNab, A. (2008) Harmonizing Standards and Coding for hESC Research. Cell Stem Cell 2, March.
- Lomax, G.P., Stayn S., (2008) Similarities and Differences Among Stem Cell Research Policies: Opportunities for Policymakers, Patients, and Researchers. Medical Research Law and Policy.11-5-08.
- Trounson A. (2008) Integration and translation: driving stem cell therapies toward the clinic. Regen Med. May;3(3):269-73.
- Trounson A, Klein R, Murphy R (2008) Stem cell research in California: the game is on. Cell Feb 22;132(4):522-4.
- Lomax, G.P., Hall, Z.W., Lo B. (2007) Responsible Oversight of Human Stem Cell Research: The California Institute for Regenerative Medicine’s Medical and Ethical Standards. PLOS Medicine May 2007, Volume 4. Issue 5 e114.
- Clinical Trials for Stem Cell Therapies
- The Promise on Hold: The Impact of the NIH Stem Cell Funding Freeze
- Policy Harmonization Through Collaboration: The Interstate Alliance on Stem Cell Research
- Stem Cell Research: A Platform for Science-Policy Innovation
- Proposed Oocyte Donation Guidelines for Stem Cell Research Fertility and Sterility
- Harmonizing Standards and Coding for hESC Research Cell Stem Cell 3/02/08
- Similarities and Differences Among Stem Cell Research Policies: Opportunities for Policymakers, Patients, and Researchers Medical Research Law & Policy 11/05/2008
- Responsible Oversight of Human Stem Cell Research: The California Institute for Regenerative Medicine’s Medical and Ethical Stan PLoS Medicine 5/07
Grantee Publications
Each scientific publication by our grantees describes an advance that could ultimately lead to new therapies.
Whitepapers on Advancing Stem Cell Therapies
On June 25, 2013, The California Institute for Regenerative Medicine (CIRM), the Alliance for Regenerative Medicine (ARM), and the Cell Therapy Catapult (Catapult) convened a roundtable on June 25, 2013 to define technological challenges and identify potential solutions in three key areas:
- Manufacturing clinical-grade cell products derived from stem cells
- Characterizing the cell product
- Imaging cells post transplantation.
This white paper summarizes the proceedings from the roundtable and highlights key recommendations
In June 2014, The California Institute for Regenerative Medicine (CIRM) convened a workshop that followed up on the 2013 Key Tools and Technology Hurdles Roundtable. The 2014 workshop further discussed technological challenges and included a proposal for a CIRM sponsored Manufacturing Center of Excellence. This white paper summarizes the proceedings from the workshop and highlights key discourse.
Commissioned Reports
We periodically commission reports by outside experts to clarify the impact of the agency on health care and the economy and to assess our effectiveness.
Economic Impacts of the California Institute for Regenerative Medicine (CIRM) (2019)
Future Health Dividend (2019)
Investing in translational research to produce clinical, commercial and financial outcomes (2013)
Updated economic impact report (2012)
Report of the CIRM External Advisory Committee
Coverage, Cost-Control Mechanisms, and Financial Risk-Sharing Alternatives of High-Cost Health Care Technologies
Supporting Diversity in Research Participation: A Framework for Action
Economic Impact of Research Funded by the California Institute for Regenerative Medicine (2010)
